Quantum Genesis AI Corp. (OTC: QGAI) released a statement on May 19, 2026, to clarify the relationship between its research activities and those of Quantumzyme LLP, a separate entity based in Bengaluru, India. The company emphasized that Quantumzyme LLP is not a subsidiary or affiliate of Quantum Genesis AI. This clarification follows prior press releases on November 5, 2025, and February 12, 2026, which referenced scientific publications in the enzyme engineering and biocatalysis field. Those publications listed Quantumzyme LLP and reflected the affiliations of researchers at the time of submission.
The company stated that scientific publications arising from research by its CEO, Naveen Kulkarni, appropriately reflect the affiliations of the contributing researchers when the research was conducted. However, Quantum Genesis AI believes that intellectual property and technology developed by Mr. Kulkarni, whether directly or through Quantumzyme LLP, that relate to the company's core enzyme engineering and biocatalysis field and are based on or derived from the transferred technology platform fall within the scope of rights transferred to the company. This transfer occurred pursuant to an Asset Purchase Agreement dated February 21, 2023, and a subsequent confirmatory assignment, as detailed in the company's Current Report on Form 8-K filed on April 29, 2026.
The company's prior disclosures regarding scientific publications were made based on its ownership of the relevant intellectual property and technology. Quantum Genesis AI is focused on enzyme engineering, molecular modeling, and biocatalysis technologies, leveraging artificial intelligence and computational modeling to support research and discovery. The company maintains a commitment to transparency and responsible corporate governance, as outlined on its website at qgaicorp.com.
This clarification is significant for investors and stakeholders, as it addresses potential confusion about the ownership of key intellectual property assets. By distinguishing itself from Quantumzyme LLP and reaffirming its IP rights, Quantum Genesis AI aims to provide clarity on the scope of its technology platform and the basis for its scientific publications. The company's ability to assert ownership over the underlying technology and methodologies is crucial for its business strategy and competitive positioning in the enzyme engineering and biocatalysis market.
The announcement also highlights the importance of the Asset Purchase Agreement and confirmatory assignment in securing the company's intellectual property. As Quantum Genesis AI continues to develop its technology and pursue commercial applications, the clarity around IP ownership will be essential for partnerships, funding, and regulatory processes. The company's forward-looking statements, as noted in the press release, involve risks and uncertainties, but this clarification aims to mitigate potential misunderstandings about the source of its research and innovations.
